ArticleJournal of neurology, neurosurgery, and psychiatry2026
Predictors of B-cell repopulation in people with multiple sclerosis treated with ocrelizumab: insights from two large cohorts.
Article in Journal of neurology, neurosurgery, and psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab.European journal of neurology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence indicates that B-cell dynamics during ocrelizumab treatment vary among individuals with multiple sclerosis. However, our understanding of B-cell dynamics is incomplete. We aim to characterise temporal profiles of CD19+ B-cell repopulation and identify demographic and clinical predictors of B-cell dynamics.
methodsThis was a retrospective multicentre cohort study including people with multiple sclerosis treated with ocrelizumab for ≥180 days from two academic centres. Variables of interest were visualised to explore their associations with CD19+ B-cell count. Generalised linear mixed effect models and logistic mixed effect models were used to identify predictors of CD19+ B-cell counts and early B-cell repopulation (>0.01×10
results567 participants, contributing 4592 CD19+ B-cell counts, were included. Younger age (β=-0.01, 95% CI -0.02 to -0.003), heavier weight (β=0.02, 95% CI 0.008 to 0.02), fewer ocrelizumab infusions (β=-0.07, 95% CI -0.08 to -0.06) and higher pre-ocrelizumab CD19+ B-cell counts (β=1.42, 95% CI 0.82 to 2.03) were associated with higher CD19+ B-cells during treatment. Pre-ocrelizumab CD19+ B-cells were higher in patients previously treated with natalizumab (mean B-cell count 0.57×10
conclusionsAge, weight, cumulative ocrelizumab exposure, pre-ocrelizumab CD19+ B-cell count and prior disease modifying therapy influence CD19+ B-cell repopulation during ocrelizumab treatment. With further elucidation of the association between B-cell dynamics and treatment effectiveness, these findings will help guide dosing of anti-CD20 therapies in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.